Filing Flows › Biolife Solutions (BLFS) › Takeover & LBO
Is Biolife Solutions (BLFS) a takeover target?
A leveraged buyout does not work for Biolife Solutions on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-09-04): Agreed sale to Repligen at $11.25 cash a share · pending.
Why a leveraged buyout does not fit
The buyout model needs Biolife Solutions' revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-09-04 · deal · Agreed sale to Repligen at $11.25 cash a share · pending
- 2026-09-04 · DEFM14A · Merger proxy (DEFM14A)
Biolife Solutions' latest quarter
Biolife Solutions, Q2 2026: revenue $28.5M (+22% year over year), operating margin 6.0%, net earnings $45.1M, operating cash flow $6.3M. The chart follows the revenue to costs, profit and cash.
Questions
Is Biolife Solutions being acquired?
The latest signal on file is from 2026-09-04: Agreed sale to Repligen at $11.25 cash a share · pending. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Biolife Solutions?
A leveraged buyout does not work for Biolife Solutions on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.